SIGHT GenSight Biologics S.A.
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa and dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.…
Industry Peers
BiotechnologyKey Statistics
About GenSight Biologics (EPA: SIGHT)
›
GenSight Biologics (EPA: SIGHT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 0.0761 EUR on 19 November 2026, down 27.5% over 52 weeks. Its 52-week range is 0.0600 EUR to 0.1490 EUR: the price is 48.9% below the high and 26.8% above the low.
Its market capitalisation is 18.67M EUR.
GenSight Biologics reports return on equity of 48.3%.
Its debt exceeds its cash by 11.16M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.